Article

Biomarkers in Patients with Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

This clinical trial is analyzing biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer and in normal volunteers.

Study Type: Observational

Age/Sex Requirement: None

Sponsor: University of Colorado at Denver and Health Sciences Center

Clinicaltrials.gov Identifier: NCT00900419

Purpose: To evaluate biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer and in normal volunteers. The primary outcome measure is genetic mutations or altered growth factor expression. The secondary outcome measure is the establishment of a tissue repository of normal and dysplastic respiratory epithelium.

Click here to access additional information from this third-party website.

Related Videos
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
© 2024 MJH Life Sciences

All rights reserved.